{"id":"mk-0524b","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL2057618","moleculeType":"Small molecule","molecularWeight":"164.16"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Glucagon receptor antagonists work by blocking the action of glucagon, a hormone that raises blood glucose levels. By inhibiting glucagon's effects, MK-0524B aims to improve glycemic control in patients with type 2 diabetes.","oneSentence":"MK-0524B is a glucagon receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:33.978Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00479882","phase":"PHASE3","title":"MK-0524B Lipid Study (MK-0524B-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":2414},{"nctId":"NCT01335997","phase":"PHASE3","title":"Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1139},{"nctId":"NCT00289900","phase":"PHASE3","title":"Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01-24","conditions":"Mixed Hyperlipidemia","enrollment":2340},{"nctId":"NCT01294683","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02-04","conditions":"Primary Hypercholesterolemia, Dyslipidemia","enrollment":977},{"nctId":"NCT00269217","phase":"PHASE3","title":"Lipid Efficacy Study (0524B-022)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":1400},{"nctId":"NCT00943124","phase":"PHASE1","title":"MK0524B Bioequivalence Study (0524B-070)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Dyslipidemia","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK-0524B","genericName":"MK-0524B","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK-0524B is a glucagon receptor antagonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}